36
Participants
Start Date
April 30, 2001
Primary Completion Date
June 30, 2005
Study Completion Date
August 31, 2010
Islet Transplantation
Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
Sirolimus
Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
Tacrolimus
Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
Daclizumab
Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
Sulfamethoxazole
An antibacterial used to prevent opportunistic infections
Ganciclovir
An antiviral used to kill viruses and stop viral replication
Trimethoprim
An antibacterial used to prevent opportunistic infections
Pentamidine
An antiprotozoal used to prevent disease
University of Miami, Miami
Justus-Leibig University, Giessen
University of Minnesota, Minneapolis
Washington University, St Louis
Benaroya Research Institute at Virginia Mason Research Center, Seattle
Massachusetts General Hospital, Boston
University of Alberta, Edmonton
University of Milan, Milan
University of Geneva, Geneva
Immune Tolerance Network (ITN)
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH